COSCIENS Biopharma Inc. (CSCI)
NASDAQ: CSCI · Real-Time Price · USD
2.981
-0.019 (-0.64%)
Nov 20, 2024, 4:00 PM EST - Market closed

Company Description

COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally.

Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.

The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson’s disease.

In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism.

The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024.

COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.

COSCIENS Biopharma Inc.
COSCIENS Biopharma logo
Country Canada
Founded 1990
IPO Date Jul 18, 1996
Industry Biotechnology
Sector Healthcare
Employees 12
CEO Gilles Gagnon

Contact Details

Address:
222 Bay Street, Suite 3000
Toronto, ON M5K 1E7
Canada
Website cosciensbio.com

Stock Details

Ticker Symbol CSCI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001113423
CUSIP Number 22112H101
ISIN Number CA22112H1010
SIC Code 2834

Key Executives

Name Position
Gilles R. Gagnon ICD.D, M.B.A., M.Sc. President, Chief Executive Officer and Director
Giuliano La Fratta Senior Vice President of Finance and Chief Financial Officer
Dr. Michael Teifel Ph.D. Senior Vice President of Non-Clinical Development and Chief Scientific Officer
Dr. Nicola Ammer M.D. Chief Medical Officer and Senior Vice President of Clinical Development
Dr. Matthias Gerlach Senior Vice President Manufacturing and Supply Chain and Head of Production

Latest SEC Filings

Date Type Title
Nov 12, 2024 6-K Report of foreign issuer
Nov 12, 2024 6-K Report of foreign issuer
Oct 8, 2024 6-K Report of foreign issuer
Oct 1, 2024 6-K Report of foreign issuer
Sep 23, 2024 6-K Report of foreign issuer
Sep 6, 2024 SC 13D General statement of acquisition of beneficial ownership
Aug 27, 2024 6-K Report of foreign issuer
Aug 13, 2024 6-K Report of foreign issuer
Aug 13, 2024 6-K Report of foreign issuer
Aug 7, 2024 6-K Report of foreign issuer